CRDF News and Press, Cardiff Oncology Inc. From 03/06/23

Cardiff Oncology Formally Introduces Scientific Advisory Board PR Newswire - SAB includes recognized leaders with expertise in oncology drug development, pharmaceutical industry dynamics and translational research – - SAB will continue to provide insight and gui...

Cardiff Oncology press release ( NASDAQ: CRDF ): FY GAAP EPS of -$0.89 beats by $0.05 . Revenue of $0.39M (+8.3% Y/Y) beats by $0.12M . For further details see: Cardiff Oncology GAAP EPS of -$0.89 beats by $0.05, revenue of $0.39M beats by $0.12M

Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update PR Newswire Phase 1b /2 trial in lead KRAS-mutated metastatic colorectal cancer (mCRC) program continues to show our lead candidate onvansertib demonstrates an objective respons...

AdaptHealth ( AHCO ) -22% on Q4 earnings release . TPI Composites ( TPIC ) -18% after launching $100M senior notes offering . Olaplex ( OLPX ) -13% on Q4 earnings release . NewtekOne ( NEWT ) -15% on Q4 earnings release . Asset Entit...

Cardiff Oncology to Present at the Cowen 43rd Annual Health Care Conference PR Newswire SAN DIEGO , Feb. 27, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology d...

Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer PR Newswire Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib ...

Palm Beach, FL – January 19, 2023 – FinancialNewsMedia.com News Commentary – Gamma Delta T Cell Therapy represents one of the most promising T Cell therapies in clinical development. The introduction of T cell-based immunotherapy has greatly revolutionized the par...

Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology Conference PR Newswire SAN DIEGO , Jan. 10, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel ther...

Summary Today, we revisit a small, promising oncology concern whose stock is down in recent months due to some strategic changes. However, the company's primary drug candidate is targeting several indications in combination therapy with large potential markets. We update the investm...

Cardiff Oncology to Present at Upcoming Investor Conferences PR Newswire SAN DIEGO , Nov. 21, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a...